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Histone deacetylase inhibitors enhance
expression of NKG2D ligands in Ewing sarcoma
and sensitize for natural killer cell-mediated
cytolysis
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Abstract
Background: Ewing sarcoma patients have a poor prognosis despite multimodal therapy. Integration of
combination immunotherapeutic strategies into first-/second-line regimens represents promising treatment options,
particularly for patients with intrinsic or acquired resistance to conventional therapies. We evaluated the
susceptibility of Ewing sarcoma to natural killer cell-based combination immunotherapy, by assessing the capacity
of histone deacetylase inhibitors to improve immune recognition and sensitize for natural killer cell cytotoxicity.
Methods: Using flow cytometry, ELISA and immunohistochemistry, expression of natural killer cell receptor ligands
was assessed in chemotherapy-sensitive/-resistant Ewing sarcoma cell lines, plasma and tumours. Natural killer cell
cytotoxicity was evaluated in Chromium release assays. Using ATM/ATR inhibitor caffeine, the contribution of the
DNA damage response pathway to histone deacetylase inhibitor-induced ligand expression was assessed.
Results: Despite comparable expression of natural killer cell receptor ligands, chemotherapy-resistant Ewing
sarcoma exhibited reduced susceptibility to resting natural killer cells. Interleukin-15-activation of natural killer cells
overcame this reduced sensitivity. Histone deacetylase inhibitor-pretreatment induced NKG2D-ligand expression in
an ATM/ATR-dependent manner and sensitized for NKG2D-dependent cytotoxicity (2/4 cell lines). NKG2D-ligands
were expressed in vivo, regardless of chemotherapy-response and disease stage. Soluble NKG2D-ligand plasma
concentrations did not differ between patients and controls.
Conclusion: Our data provide a rationale for combination immunotherapy involving immune effector and target
cell manipulation in first-/second-line treatment regimens for Ewing sarcoma.
Keywords: Ewing sarcoma, natural killer cells, histone deacetylase inhibitor, combination immunotherapy, che-
motherapy-resistance, tumour immunology
Introduction
Ewing sarcoma is an aggressive round cell sarcoma
characterized by specific gene fusions most commonly
involving TET gene family products, though rarely other
activating transcription factors [1-3]. It usually affects
bone or soft tissue in children and young adults. Despite
multimodal therapy consisting of high-dose
chemotherapy, surgery and radiotherapy, survival of
patients with Ewing sarcoma has not improved signifi-
cantly during the past decade. Patients with therapy-
resistant or metastatic Ewing sarcoma have the most
unfavorable prognosis, with a 5-year overall survival of
less than 30% [4-6], which has recently been demon-
strated to be independent of Ewing sarcoma-ETS fusion
type [4,5].
Natural killer (NK) cells are the main cytotoxic effec-
tor cells of the innate immune system, contributing to
host anti-microbial and anti-tumour immune responses.
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In contrast to T-lymphocytes, these cells lack antigen-
specific receptors. Instead, recognition of target cells
and subsequent triggering of effector functions is regu-
lated by integration of signals delivered from inhibitory
(e.g. killer cell immunoglobulin receptors, CD94/
NKG2A) and activating (e.g. natural killer group 2D
(NKG2D), DNAX accessory molecule 1 (DNAM1), nat-
ural cytotoxicity receptor (NCR)) cell surface receptors
[7,8]. Natural killer cells respond to several cytokines,
including several interleukins and type I interferons,
resulting in increased cytolytic, secretory and prolifera-
tive capacity [9]. Several studies have addressed the
therapeutic potential and safety of immunotherapeutic/
natural killer cell-based approaches for various cancer
types, including sarcomas [10-15]. Sensitivity of tumours
to natural killer cells critically depends on expression of
ligands for activating receptors. Likewise, low expression
of inhibitory human leukocyte antigen (HLA) class I
molecules is an important prerequisite for successful
natural killer cell triggering. Manipulation of either the
balance between activating and inhibitory signals (by,
for instance, ex vivo activation of immune cells) and/or
sensitization of target cells for immune-mediated killing
by combination immunotherapy may improve immu-
notherapeutic efficacy. For example, pre-conditioning of
various cancer cell types by agents that activate the
DNA damage response pathway may sensitize for nat-
ural killer cell cytotoxicity via induction of activating
natural killer cell receptor ligands and/or death receptor
expression. Comparable results have been observed for
histone deacetylase inhibitors (HDI), which are currently
emerging as potent anti-tumour agents [16-19].
Pre-clinical studies show that Ewing sarcoma can be
targeted by (cytokine-activated) natural killer cells in a
NKG2D-, DNAM1- and, as recently demonstrated,
NCR-dependent manner [20-24]. Moreover, a potential
role for natural killer cell alloreactivity in Ewing sarcoma
disease control has recently been suggested [25]. Inte-
gration of natural killer cell-based (combination) immu-
notherapy into first-line treatment regimens or as a
second-line approach represents a promising treatment
option for Ewing sarcoma, in particular for patients with
either intrinsic or acquired resistance to conventional
therapies [26]. However, chemotherapy-resistance of
Ewing sarcoma correlates with expression of genes
involved in, among others, apoptosis signaling pathways
[27]. Depending on the (apoptotic) pathways involved,
resistance to apoptosis might render cells cross-resistant
to immune cell cytotoxicity [28]. As yet, data about the
susceptibility of therapy-resistant Ewing sarcoma to nat-
ural killer cell cytotoxicity are lacking. To obtain insight
into the potential of natural killer cell-based combina-
tion immunotherapy for Ewing sarcoma, natural killer
cell receptor ligand expression and susceptibility to
natural killer cell cytotoxicity were evaluated in che-
motherapy-sensitive and -resistant Ewing sarcoma
tumour samples and cell lines respectively. Moreover,
since HDI have the ability to exhibit direct cytotoxicity
against Ewing sarcoma in vitro as well as in vivo and to
sensitize for both conventional and more experimental
treatment modalities [29-32], the potential of these
agents to sensitize Ewing sarcoma for natural killer cell
cytotoxicity was investigated.
Methods
Ewing sarcoma patients and samples
Peripheral blood samples from newly diagnosed Ewing
sarcoma patients (2004-2009) were collected prior to
start of chemotherapy (n = 27) and, in case of complete
remission, six months after completion of therapy (n =
7) (treatment according to the EURO-EWING 99 trial
[4]). Samples were centrifuged immediately and plasma
was stored at -80°C until assayed. Mean age at diagnosis
was 20.8 years (range 4-61 years). Plasma obtained from
age-comparable healthy controls (n = 27; mean age 21.8,
range 5-65 years) was used as a reference. Formalin-
fixed paraffin-embedded, sequential pre-treatment, post-
chemotherapy and recurrent metastatic tumour samples
(n = 33) from eight Ewing sarcoma patients were
obtained from the Department of Pathology, Leiden
University Medical Center. In all cases, diagnosis was
established according to WHO criteria including stan-
dard confirmatory immunohistochemistry and fusion
transcript type. Follow-up provided information con-
cerning initial tumour stage, (histological) chemotherapy
response [33], recurrence rate and performance state.
All patient material was coded, such that correlation
with clinical data was only possible for physicians
involved in treatment of the patients. Subsequent
research was conducted following the ethical guidelines
of the Dutch organization of scientific societies
(FEDERA).
Ewing sarcoma cell lines
Ewing sarcoma cell lines SK-ES-1, SK-N-MC, CADO-ES
and STA-ET2.1 [34] were cultured in RPMI-1640 sup-
plemented with streptomycin/penicillin (Invitrogen,
Paisley, United Kingdom) and 10% fetal bovine serum
((FBS); Greiner Bio-One, Alphen a/d Rijn, The Nether-
lands). TC71 [34] and IOR/BER (kindly provided by dr.
K. Scotlandi, Instituto Orthopedico Rizzoli, Bologna,
Italy) were cultured in Iscove’s Modified Dulbecco’s
Medium supplemented with streptomycin/penicillin and
10% FBS. Previously reported [27,35] ‘natural’ sensitivity
of these cell lines to chemotherapeutic drugs currently
used for treatment of Ewing sarcoma [4] was used to
discriminate chemotherapy-sensitive (TC71, SK-ES-1,
SK-N-MC) from chemotherapy-resistant (STA-ET2.1,
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CADO-ES, IOR/BER) cell lines. Molecular HLA typing
of the cell lines, performed at Leiden University Medical
Center (LUMC), was converted to serological equiva-
lents (no serological equivalents exist for HLA-Cw*16
and -Cw*12): SK-ES-1 (A2/A11/B7/B44/Cw5/Cw7), SK-
N-MC (A1/A25/B8/Cw7), CADO-ES (A11/A24/B15/
B40/Cw4/Cw7), STA-ET-2.1 (A11/A24/B18/B40/Cw2/
Cw5), TC71 (A2/A68/B15/B44/Cw3/Cw5), IOR/BER
(A2/A11/B18/B51/Cw7/Cw15). The EBV B-LCL 107 cell
line was generated from a healthy blood bank donor
expressing HLA alleles which are ligands to all inhibi-
tory killer cell immunoglobulin receptors [20]. The
human erythroleukemia cell line K562 was obtained
from American Type Culture Collection (Manassas,
VA). Cell lines were routinely screened for mycoplasma
contamination. Periodical authentication was performed
by Short Tandem Repeat profiling and molecular HLA
typing.
Antibodies and reagents
The antibodies used for staining of antigens by flow
cytometry and immunohistochemistry as well as for
blocking of specific natural killer cell receptors and
detection of soluble protein by ELISA are described in
additional file 1, table S1. HDI [N-(2-amino-phenyl)-4-
[N-(pyridine-3-ylmethoxycarbonyl)aminomethyl]benza-
mide] (MS-275) and suberoylanilide hydroxamic acid
(SAHA) were purchased from Enzo Life Sciences
(Raamsdonksveer, The Netherlands). Sodium butyrate
(NaB) and the pharmacological ATM/ATR inhibitor caf-
feine were obtained from Sigma-Aldrich (Zwijndrecht,
The Netherlands).
Flow cytometric analysis of antigen surface expression
Flow cytometric analysis was performed on a FACScali-
bur (Beckton Dickinson, Franklin Lakes, NJ) and results
were analyzed using Cellquest software, as previously
described [36]. Ligand expression was represented as
fold increase in Mean Fluorescence Intensity (MFI) over
isotype control staining (MFI-ratio).
Immunohistochemistry for detection of NKG2D ligand
expression in Ewing sarcoma tumour samples
4-μm sections containing representative tumour were
deparaffinized and citrate antigen retrieval was per-
formed. Subsequent immunohistochemical stainings
were performed and (semi-quantitatively) scored as pre-
viously described [36].
Quantification of soluble MICA in Ewing sarcoma patient
plasma samples
Concentrations of soluble MICA in plasma samples
were determined by sandwich-ELISA using the MICA
(human) detection set, according to the manufacturer’s
protocol (BAMOMAB/Axxora, Lörrach, Germany). In
short, plates were coated overnight at 4°C with 5 μg/ml
of the anti-MICA antibody (AMO1). After blocking with
15% BSA/PBS for 15 minutes at 37°C, plates were
washed with 0.05% Tween-20/PBS. Samples or recombi-
nant MICA*04, serving as a standard, were added in
7.5% BSA/PBS. After incubation for two hours at 37°C
and washing, detection antibody (anti-MICA/B
(BAMO3)) was added at a concentration of 1 μg/ml
(two hours, 37°C). Plates were washed and incubated
with HRP-conjugated anti-mouse IgG2a antibody (1080-
05; SouthernBiotech, Birmingham, AL) for one hour at
37°C. After extensive washing, TMB peroxidase sub-
strate (KPL, Gaithersburg, MD) was added and plates
were incubated for 35 minutes at room temperature in
the dark. HRP activity was stopped by addition of 1 M
phosphoric acid and absorbance was measured at 450
nm wavelength.
Isolation of natural killer cells from healthy donor-derived
peripheral blood mononuclear cells
Peripheral blood mononuclear cells were obtained
from healthy blood bank donors after informed con-
sent and were isolated using Ficoll density gradient
separation. Isolation of natural killer cells was per-
formed using the MACS NK enrichment kit and LS
columns, according to the manufacturer ’s protocol
(Miltenyi Biotec, Bergisch Gladbach, Germany) and
isolated cells were plated for overnight recovery at 1-2
× 106 cells/ml in RPMI-1640 supplemented with strep-
tomycin/penicillin and 10% FBS. As determined by
flow cytometric analysis, natural killer cell purity
always exceeded 88% and T-cell contamination > 0.2%
was never detected. For cytokine activation, natural
killer cells were cultured in AIM-V medium (Invitro-
gen), supplemented with 10% pooled human AB-serum
(Sanquin, Rotterdam, The Netherlands) and streptomy-
cin/penicillin and stimulated with 10 ng/ml recombi-
nant human interleukin-15 (IL-15) (Bender Medical
Systems, Vienna, Austria). Activated natural killer cells
were used for Chromium (51Cr) release assays within
two-four weeks of culture.
Evaluation of natural killer cell cytotoxicity by Chromium
release assays
Cytotoxicity was determined in standard 4-hour 51Cr
release assays as previously described [20]. For specific
natural killer cell receptor (ligand) blocking, natural
killer cells or target cells were pre-incubated with
blocking antibodies (20 μg/ml; additional file 1, table
S1) at room temperature for 20 minutes prior to the
51Cr release assay. We previously demonstrated that
pre-incubation of natural killer cells with control iso-
type (IgG1)-matched antibody (anti-CD56) did not
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affect cytotoxicity [20]. Moreover, pre-incubation of
Ewing sarcoma cells with control isotype (IgG1)-
matched antibody (anti-CD99; clone B-N24; Diaclone/
Sanquin Reagents, Amsterdam, Netherlands) had no
effect on natural killer cell-mediated cytolysis (data not
shown).
Pre-treatment of Ewing sarcoma cell lines with histone
deacetylase inhibitors
Ewing sarcoma cell lines SK-ES-1, CADO-ES, STA-
ET2.1 and TC71 were seeded in 96 well plates at cell
densities ranging from 3-15 × 103 cells/well. Following
overnight attachment, cells were incubated for 24
hours with increasing concentrations of specific HDI.
Cell viability was measured by 3-(4,5-dimethyl-thiazol-
2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) cell viability assay (Promega
Benelux, Leiden, The Netherlands). The cytotoxic
effect of HDI was quantified by determining IC50
values, as defined by the concentration of drug at
which 50% of the cells were still metabolically active
(table 1). For analysis of phenotypical and functional
consequences of HDI treatment, cell lines were pre-
treated with defined concentrations of HDI, as indi-
cated in the results section. After 24 hours, cells were
harvested, washed and included in flow cytometric or
cytotoxicity analyses. In some experiments, cells were
pre-incubated for two hours with ATM/ATR inhibitor
caffeine (optimal dose based on dose response curve
(data not shown)).
Statistical analyses and artwork
Statistical analyses were performed with SPSS version
16.0 software package. (Paired) t-tests or one-way
ANOVA tests were used for comparison of means
within or between samples or groups of samples. P <
0.05 was considered statistically significant. Artwork was
created using Graphpad Prism 5.0 (La Jolla, CA).
Results
Chemotherapy-resistant Ewing sarcoma exhibit reduced
susceptibility to lysis by resting natural killer cells
To assess possible cross-resistance of chemotherapy-
resistant Ewing sarcoma to natural killer cell cytotoxi-
city, a panel of both chemotherapy-sensitive (n = 3;
TC71, SK-ES-1, SK-N-MC) and -resistant (n = 3;
STA-ET2.1, CADO-ES, IOR/BER) cell lines was evalu-
ated for susceptibility to lysis by resting natural killer
cells obtained from 4-8 healthy donors. As illustrated
in Figure 1A-B, 51Cr release assays revealed signifi-
cantly reduced sensitivity of chemotherapy-resistant
cell lines to resting natural killer cell-mediated cytoly-
sis, at effector-to-target ratio ’s ≥ 2.5:1 (t-test, p <
0.05).
Comparable expression of ligands for activating and
inhibitory natural killer cell receptors in chemotherapy-
sensitive and -resistant Ewing sarcoma
Natural killer cell cytotoxicity to Ewing sarcoma cells
critically depends on combined NKG2D and DNAM1
signaling [20,23]. Therefore, constitutive surface expres-
sion of ligands for these activating natural killer cell
receptors was analyzed in our panel of Ewing sarcoma
cell lines by flow cytometry. As represented in Figures
2A-B and additional file 2, figure S1A, flow cytometric
analysis revealed no significant differences between che-
motherapy-sensitive and -resistant cell lines with regard
to expression of ligands for activating natural killer cell
receptors NKG2D (MICA, MICB, ULBP1-3) and
DNAM1 (CD112, CD155) or killer cell immunoglobulin
receptors (HLA class I) (additional file 2, figure S1A, t-
test, p > 0.05). Considerable inter-cell line variation,
however, was observed for HLA class I expression: che-
motherapy-resistant CADO-ES cells, demonstrating sub-
stantial resistance to natural killer cells, exhibited 50-
fold higher HLA class I expression as compared to che-
motherapy-/natural killer cell-sensitive SK-ES-1 cells
(Figure 1A and 2A). However, and consistent with pre-
vious observations [20], blocking of HLA class I expres-
sion could not restore the difference in natural killer
cell susceptibility between chemotherapy-sensitive and
-resistant cell lines (additional file 2, figure S1B). In
addition, and consistent with the observed comparable
ligand expression, blocking of NKG2D and DNAM1 on
resting natural killer cells in 51Cr release assays reduced
natural killer cell-mediated cytolysis of both chemother-
apy-sensitive and -resistant cell lines to a similar degree
(data not shown).
Immunohistochemical staining for expression of
NKG2D-ligands MICA and ULBP1 in sequential pri-
mary Ewing sarcoma tumour samples obtained from
patients with different histological responses to
Table 1 In vitro cytotoxicity (IC50 values) of histone
deacetylase inhibitors to chemo-sensitive and -resistant
EWS cell linesa
cell line NaB (mM) SAHA (μM) MS-275 (μM)
chemo-sensitive
SK-ES-1 1.43 2.85 3.72
TC71 7.85 2.96 30.71
chemo-resistant
CADO-ES 38.99 3.92 49.97
STA-ET2.1 0.61 1.58 10.06
a ’natural’ sensitivity of specific cell lines to chemotherapeutic drugs, as
previously described [27,35].
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chemotherapy [33] demonstrated abundant expression
of (at least one of) these activating ligands throughout
all stages of disease and regardless of the histological
response to chemotherapy (table 2; Figure 2C-D). In
summary, both in vitro as well as in vivo, natural killer
cell receptor ligands are expressed regardless of che-
motherapy-sensitivity.
MICA plasma levels are not elevated in Ewing sarcoma
patients
Shedding of NKG2D ligands, in particular MICA, from
the cell surface represents a mechanism by which
tumours escape NKG2D immune surveillance [37-39].
Therefore, and based on the in situ expression of MICA
in Ewing sarcoma tumours, soluble MICA expression
Figure 1 Chemotherapy-resistant Ewing sarcoma display significantly reduced susceptibility to lysis by resting natural killer cells. A-B.
Cytotoxic activity of resting natural killer cells was evaluated in 51Cr release assays using chemotherapy-sensitive (grey) and -resistant (black)
Ewing sarcoma cell lines TC71 (grey dots), SK-ES-1 (grey squares) and SK-N-MC (grey triangles) respectively STA-ET2.1 (black squares), CADO-ES
(black dots) and IOR/BER (black triangles) as target cells. Classical natural killer cell target K562 and EBV B-LCL cell line 107 were used as positive
and negative control respectively (A). Results are expressed as the mean ± SEM percentage of specific lysis obtained in at least four independent
experiments using different healthy donors. Statistical analysis (t-test) was performed on mean percentages of specific lysis of chemotherapy-
sensitive versus -resistant cell lines, revealing significantly reduced sensitivity of chemotherapy-resistant cell lines to resting natural killer cell-
mediated cytolysis at all effector-to-target ratio’s ≥ 2.5:1 (p < 0.05) (B).
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levels were measured in plasma samples from Ewing sar-
coma patients. Results were compared to those obtained
in plasma samples from age-comparable healthy controls.
The majority of plasma samples from healthy controls
contained levels of soluble MICA close to the lower detec-
tion limit (10 pg/ml) of the assay (median 10 pg/ml; mean
39.63 pg/ml). Plasma concentrations of soluble MICA in
patients prior to treatment (median 10 pg/ml; mean 17.67
pg/ml) or after completion of therapy (median 10 pg/ml;
mean 25.14 pg/ml) did not significantly differ from those
observed in healthy controls (one-way ANOVA, p > 0.05)
(Figure 2E).
Chemotherapy-sensitive and -resistant Ewing sarcoma
demonstrate comparable susceptibility to IL-15-activated
natural killer cells
Pre-activation of natural killer cells by either recombi-
nant human IL-15 or co-culture with genetically modi-
fied IL-15/4-1BBL expressing K562 feeder cells results
in more efficient recognition and lysis of Ewing sarcoma
cells [20,23]. Therefore, we evaluated whether the
reduced sensitivity of chemotherapy-resistant Ewing sar-
coma cell lines to resting natural killer cells could be
restored by using IL-15-activated natural killer cells
(including cells obtained from donors providing resting
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Figure 2 Non-differential expression of natural killer cell receptor ligands among chemotherapy-sensitive and -resistant Ewing
sarcoma in vitro or in vivo. A. Constitutive surface expression of inhibitory (HLA class I) or activating (MICA/B, ULBP1-3, CD112, CD155) natural
killer cell receptor ligands in chemotherapy-sensitive (grey; TC71, SK-ES-1 and SK-N-MC) and -resistant (black; CADO-ES, STA-ET2.1 and IOR/BER)
Ewing sarcoma cell lines, as assessed by flow cytometry. Results are expressed as the mean ± SD MFI-ratio, obtained in at least two independent
experiments. B. Representative examples of flow cytometry plots for HLA class I, MICB and ULBP-2 for several Ewing sarcoma cell lines; isotype
matched control staining is shown in grey. C-D. Light micrographs (20 × magnification) of immunohistochemical stainings for MICA (c; strong
expression) and ULBP-1 (d; moderate expression) in sequential primary Ewing sarcoma tumours. E. ELISA for detection of soluble MICA in plasma
samples obtained from Ewing sarcoma patients (either prior to start of chemotherapy (’pre-treatment’) or after completion of therapy (’post-
treatment’)) and age-comparable controls (’controls’). Statistical analysis (one-way ANOVA) revealed no significant differences in mean soluble
MICA levels among ‘controls’ (39.63 pg/ml), ‘pre-treatment’ (17.67 pg/ml) or ‘post-treatment’ (25.14 pg/ml) patients (p > 0.05).
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natural killer cells). As illustrated in Figure 3, activation
of natural killer cells with IL-15 increased specific cyto-
lysis of chemotherapy-resistant Ewing sarcoma to levels
similar to those observed for chemotherapy-sensitive
cells. Blocking studies using antibodies against NKG2D
and DNAM1 revealed comparable contributions of sig-
nals provided by these activating natural killer cell
receptors to lysis of both chemotherapy-sensitive and
-resistant cells (as exemplified for TC71, SK-ES-1, STA-
ET2.1 and CADO-ES in additional file 3, figure S2).
Together, these data indicate that pre-activation of nat-
ural killer cells with IL-15 can overcome resistance of
chemotherapy-resistant Ewing sarcoma to natural killer
cell-mediated cytolysis.
Histone deacetylase inhibitors induce NKG2D ligand
expression in Ewing sarcoma in an ATM/ATR-dependent
manner
To assess the capacity of HDI to sensitize Ewing sar-
coma for immune-mediated cytotoxicity, cell lines were
exposed for 24 hours to HDI belonging to three differ-
ent structural classes: hydroxamic acid SAHA, short-
chain fatty acid NaB and benzamide MS-275. Analysis
of the direct cytotoxic effects of these drugs by cell via-
bility assays revealed variation in the sensitivity of the
different cell lines to these agents, as represented by var-
iances in drug-specific IC50 values (table 1).
Flow cytometric evaluation of natural killer cell recep-
tor ligand expression upon 24-hour pre-treatment of the
cell lines with defined (IC50-related) concentrations of
HDI revealed heterogeneous but consistent induction of
several activating NKG2D ligands, in particular MICB,
in all cell lines evaluated. The most pronounced effects
were observed upon pre-treatment with NaB and MS-
275, resulting in up to five-fold induction of MICB (Fig-
ure 4A-D). Expression of activating DNAM1 ligands
(CD112 and CD155) remained largely unchanged.
Induction of HLA class I expression was detectable in
cell lines STA-ET2.1 and TC71, whereas in CADO-ES,
with relatively high levels of constitutive HLA class I
expression (Figure 2A), no induction was observed.
Induction of HLA class I expression was demonstrated
in the SK-ES-1 cell line as well. However, since constitu-
tive HLA class I expression was hardly detectable in this
cell line (Figure 2A), the observed less than two-fold
induction by histone deacetylase inhibitors still resulted
in marginal HLA class I expression (Figure 4A-C).
In addition to a direct epigenetic effect resulting in
increased expression of target genes, HDI may induce
activation of the ATM/ATR-mediated DNA damage
response which, in turn, induces NKG2D ligand expres-
sion [16]. To assess whether the ATM/ATR response
pathway contributed to HDI-induced expression of
NKG2D ligands in Ewing sarcoma cells, cell lines were
treated with ATM/ATR inhibitor caffeine (5 mM) for 2
hours prior to incubation with these agents. Indeed, caf-
feine pre-treatment largely prevented HDI-mediated
induction of NKG2D ligands, but not HLA class I, in all
cell lines (as exemplified for MICB/HLA class I expres-
sion upon MS-275 in Figure 4E).
Table 2 In vivo NKG2D ligand expression in sequential
Ewing sarcoma tumour samples
UPNa sample type (years after diagnosis) MICA ULBP1
1 post-chemotherapy resection-GRb n.e. +
lung metastasis (2) ++ +
mediastinal metastasis (3) ++ +
2 pre-treatment biopsy ++ +
post-chemotherapy resection-GR + ++
lung metastasis (5) + +/-
lymph node metastasis (9) ++ n.e.
3 pre-treatment biopsy + +
post-chemotherapy resection-GR ++ +
lung metastasis (3) + ++
lung metastasis (4) + n.e.
4 pre-treatment biopsy + +
post-chemotherapy resection-PRc ++ +
bone metastasis (1) ++ -
5 pre-treatment biopsy ++ +/-
post-chemotherapy resection-PR ++ +
lung metastasis (1) ++ +/-
6 pre-treatment biopsy ++ -
post-chemotherapy resection-PR ++ +/-
lung metastasis (0.5) ++ -
lung metastasis (2.5) ++ +/-
lung metastasis (3) ++ +/-
bone metastasis (3) ++ -
7 post-chemotherapy resection-PR ++ +/-
lung metastasis (1.5) ++ +
bone metastasis (2.5) ++ +/-
lung metastasis (4) ++ +
lung metastasis (4) ++ +/-
lung metastasis (5) ++ ++
paravertebral metastasis (5) ++ +
8 pre-treatment biopsy ++ +
post-chemotherapy resection-GR + n.e.
lung metastasis (8) ++ +
aUPN = unique patient number. bGR = good chemotherapy response. cPR =
poor chemotherapy
response. n.e. = not evaluable.-= absent, +/- = weak, + = moderate, ++ =
strong expression.
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Histone deacetylase inhibitors sensitize Ewing sarcoma
for NKG2D-dependent natural killer cell cytotoxicity
To assess the functional relevance of HDI-induced
alterations in natural killer cell receptor ligand expres-
sion, HDI pre-treated Ewing sarcoma cells were sub-
jected to 51Cr release assays using resting natural killer
cells. Pre-treatment of the chemotherapy-resistant
CADO-ES cell line with HDI NaB, MS-275 and SAHA
sensitized, in a dose-dependent manner, for natural
killer cell cytotoxicity (as shown for NaB in Figure 4F;
paired t-test (medium versus 1/20 of IC50 value), p <
0.05 at effector-to-target ratio’s ≥ 5:1). Similarly, pre-
treatment of SK-ES-1 cells with SAHA (1/5 of IC50
value), but not NaB or MS-275, resulted in significantly
increased cytolysis (data not shown). In cell lines TC71
and STA-ET2.1, despite induction of activating NKG2D
ligands, no sensitization for natural killer cell cytotoxi-
city was detectable (additional file 4, figure S3A). The
role of NKG2D in natural killer cell recognition and
cytolysis of HDI-treated Ewing sarcoma cells was evalu-
ated by performing 51Cr release assays in the presence
of a blocking antibody against NKG2D. In both CADO-
ES and SK-ES-1 cells, these experiments revealed (per-
sistent) dependence on signaling via this activating nat-
ural killer cell receptor since blocking reduced lysis of
both untreated and HDI-treated cells (as demonstrated
for CADO-ES upon NaB in additional file 4, figure S3B).
Discussion
Despite current multimodal therapy consisting of high-
dose chemotherapy, surgery and radiotherapy, survival
of patients with Ewing sarcoma has not improved dur-
ing the past decade. Integration of natural killer cell-
based combination immunotherapy into first-line treat-
ment regimens or as a second-line approach, as recently
emphasized by Ahn et al. [26], represents a promising
treatment option for Ewing sarcoma, in particular for
patients with either intrinsic or acquired therapy-resis-
tance. Current immunotherapeutic strategies presume
therapy-resistant tumours to be sensitive to immune-
mediated cytotoxicity. However, depending on the path-
ways involved, resistance to conventional therapies
might render cells cross-resistant to immunotherapy
[28]. The observed reduced susceptibility of chemother-
apy-resistant Ewing sarcoma to resting natural killer cell
cytotoxicity might be indicative for the existence of
cross-resistance mechanisms.
Resistance of Ewing sarcoma to chemotherapy corre-
lates (inversely) with differential expression of genes
involved in apoptosis, including caspase-8 and p53 path-
ways [27,40,41]. Based on available data about caspase-8
expression and p53 mutation status in our panel of cell
lines [27,34,36,42-44], however, the observed cross-resis-
tance to resting natural killer cells cannot be explained
by aberrant expression or the mutation status of these
Figure 3 Activation of natural killer cells with interleukin-15 restores specific cytolysis of chemotherapy-resistant Ewing sarcoma cells
to levels similar to those observed for chemotherapy-sensitive cells. Cytotoxic activity of IL-15-activated natural killer cells was evaluated in
51Cr release assays using chemotherapy-sensitive (grey) and -resistant (black) Ewing sarcoma cell lines TC71 (grey dots), SK-ES-1 (grey squares)
and SK-N-MC (grey triangles) respectively STA-ET2.1 (black squares), CADO-ES (black dots) and IOR/BER (black triangles) as target cells. K562 and
EBV B-LCL cell line 107 were used as positive and negative control respectively. Results are expressed as the mean ± SEM percentages of specific
lysis obtained in at least four independent experiments using different healthy donors.
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proteins alone. P-glycoprotein is a drug-efflux pump
that confers multidrug resistance to a wide range of che-
motherapeutic drugs, including key chemotherapeutic
agents used for Ewing sarcoma treatment [4,45]. In
addition to its ability to efflux drugs, P-glycoprotein reg-
ulates apoptosis by inhibition of caspase activation [46].
Theoretically, P-glycoprotein expression in our panel of
cell lines might contribute to the observed (relative)
cross-resistance to natural killer cells [47,48]. However,
whereas caspase-dependent apoptosis is prevented, P-
glycoprotein expressing cells remain sensitive to per-
forin/granzyme B-induced cell death [46]. We previously
demonstrated natural killer cell-mediated apoptosis
induction in Ewing sarcoma cells to be largely depen-
dent on the perforin/granzyme B-mediated granule exo-
cytosis pathway rather than on caspase-dependent death
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Figure 4 Histone deacetylase inhibitor-induced, ATM/ATR-dependent NKG2D ligand expression sensitizes Ewing sarcoma for natural
killer cell cytotoxicity. A-C. Heterogeneous induction of activating NKG2D ligands and/or inhibitory HLA class I molecules in chemotherapy-
sensitive (grey) and -resistant (black) cell lines upon pre-treatment with HDI NaB (A), MS-275 (B) and SAHA (C), as assessed by flow cytometry.
Results are expressed as mean ± SEM fold increase in MFI-ratio over medium control, obtained in at least three independent experiments. [HDI]
= 1/5 IC50 value, except for CADO-ES (NaB 1/20 IC50 value; MS-275 and SAHA 1/10 IC50 value). D. Representative examples of flow cytometry
plots for MICB for SK-ES-1 and CADO-ES upon pre-treatment with HDI MS-275 (IC50 values); untreated cells in grey. E. Pre-treatment with caffeine
(5 mM) for 2 hours prior to incubation with HDI MS-275 (1/5 of IC50 value) largely abolished HDI-mediated MICB expression (similar results were
observed for MICA and ULBP2-3), as assessed by flow cytometry. No such effects were observed for HLA class I expression. Results are expressed
as the mean ± SEM fold increase in MFI-ratio over medium control, and are representative of at least two independent experiments. Similar
results were obtained for NaB and SAHA (not shown). F. Cytotoxicity of resting natural killer cells was evaluated in 51Cr release assays. Pre-
treatment of CADO-ES cells with NaB (1/20 and 1/10 IC50 value) sensitized, in a dose-dependent manner, for natural killer cell cytotoxicity.
Statistical analysis (paired t-test) revealed significantly increased sensitivity of NaB pre-treated cells at effector-to-target ratio’s > 5:1 (p < 0.05).
Similar results were observed for CADO-ES with MS-275 and SAHA, and for SK-ES-1 with SAHA (not shown).
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receptor pathways [36]. Therefore, we assume P-glyco-
protein expression a non-crucial factor in cross-resis-
tance of Ewing sarcoma to immune-mediated
cytotoxicity. Since susceptibility of Ewing sarcoma to
natural killer cell-mediated lysis depends on expression
of ligands for activating and inhibitory natural killer cell
receptors [20,23,24], differential expression of these
ligands among chemotherapy-sensitive and -resistant
cells could be an alternative explanation for the
observed chemo-/immunotherapy cross-resistance of
Ewing sarcoma. Considerable inter-cell line variation
was observed for HLA class I expression, with a 50-fold
increased expression in chemotherapy- and natural killer
cell-resistant CADO-ES cells as compared to che-
motherapy-/natural killer cell-sensitive SK-ES-1 cells. In
a recent report, Holmes et al. [24] point to the existence
of natural killer cell activation/inhibition thresholds that
allow small changes in HLA class I cell surface expres-
sion to dramatically alter susceptibility of Ewing sar-
coma to natural killer cells. However, no significant
effects of HLA class I blocking were observed (current
and previous studies [20]), excluding a major contribu-
tion of dominant inhibitory signals provided by (differ-
ential) HLA class I expression. Moreover, and in
addition to the observed comparable constitutive expres-
sion of activating NKG2D and DNAM1-ligands, block-
ing of NKG2D and DNAM1 on resting natural killer
cells reduced natural killer cell-mediated cytolysis of
both chemotherapy-sensitive and -resistant cells to a
similar degree. Together, our results point to the exis-
tence of true cross-resistance to immune-mediated cyto-
lysis rather than to dissimilar expression of activating/
inhibitory natural killer cell receptor ligands or differen-
tial dependency on signaling via activating receptors
NKG2D and DNAM1. As yet, since ligands for activat-
ing NCR are largely unknown [7,24,49], a possible con-
tribution of such ligand can not be excluded. Similary,
other possible causes for cross-resistance to conven-
tional and immunotherapeutic approaches in Ewing sar-
coma, that have not been addressed (e.g. (over)
expression of (other) pro- or anti-apoptotic factors [50]
or dysregulation of specific signaling pathways [51]),
may need further investigation.
Importantly, the relative resistance of chemotherapy-
resistant Ewing sarcoma cells to lysis by resting natural
killer cells could be overcome by pre-activation of nat-
ural killer cells with IL-15. Although the exact mechan-
isms underlying cross-resistance to chemotherapeutic
drugs and immune-mediated cytotoxicity have not been
fully elucidated, utilization of complementary (apoptotic)
pathways or stronger pro-apoptotic signals by cytokine-
activated natural killer cells [52] may contribute to the
observed increased cytotoxic potential of these cells
toward (chemotherapy-resistant) Ewing sarcoma.
Irrespective of the exact mechanism, however, the
observation that chemotherapy-resistant Ewing sarcoma
do not exhibit cross-resistance to IL-15-activated natural
killer cell-mediated immunotherapy suggests that cyto-
kine-activated natural killer cell therapies may represent
promising immunotherapeutic options for patients with
Ewing sarcoma.
Due to the nature of this (bone) tumour, attempts to
establish primary tumour cell cultures from therapy-
naive biopsies for evaluation of natural killer cell cyto-
toxicity towards these targets have so far been unsuc-
cessful. Support for potential in vivo immune
recognition of Ewing sarcoma tumours, however, was
provided by immunohistochemical analysis of sequential
Ewing sarcoma tumour samples demonstrating expres-
sion of (at least one of the) activating natural killer cell
receptor ligands MICA and ULBP1 throughout all stages
of disease and regardless of the histological response to
chemotherapy. Moreover, and similar to previous obser-
vations in leukemia [10], a potential role for natural
killer cell alloreactivity in Ewing sarcoma disease control
has been suggested [25]. In addition to recognition by
natural killer cells, expression of NKG2D ligands might
improve anti-tumour immune responses by specific T-
lymphocyte subsets [53]. We recently reported on the
(prognostically beneficial) impact of tumour-infiltrating
T-lymphocytes on tumour progression in therapy-naive
Ewing sarcoma [54]. Despite in situ expression of
NKG2D ligands, tumour cells may escape from NKG2D
immunosurveillance by (enhanced) shedding of these
ligands from their cell surfaces. Subsequently, circulating
tumour-derived soluble ligands may cause downregula-
tion of NKG2D and, in turn, severely impair cytotoxic
effector functions of both T- and natural killer cells
[37-39]. Based on our current results demonstrating
non-elevated soluble MICA levels in plasma of Ewing
sarcoma patients (as compared to age-comparable
healthy controls) as well as our previous observation of
intact NKG2D expression on natural killer cells of these
patients [20], we do not consider NKG2D ligand shed-
ding a relevant immune escape mechanism in patients
with this tumour. We previously reported on reduced
levels of HLA class I expression in advanced-stage
Ewing sarcoma as a potential immune escape mechan-
ism hampering recognition by tumour-reactive T-lym-
phocytes and feasibility of T cell-based
immunotherapeutic approaches [55]. Our current obser-
vations of 1) in situ expression of ligands for activating
natural killer cell receptors throughout all stages of dis-
ease, including (chemotherapy-resistant) metastatic dis-
ease, 2) the absence of (enhanced) shedding of these
activating natural killer cell receptor ligands, 3) the
above mentioned reduced expression of inhibitory HLA
class I molecules in advanced-stage Ewing sarcoma
Berghuis et al. Clinical Sarcoma Research 2012, 2:8
http://www.clinicalsarcomaresearch.com/content/2/1/8
Page 10 of 13
cases and 4) the observed susceptibility of (chemother-
apy-resistant) Ewing sarcoma to IL-15-activated natural
killer cells further support the potential of Ewing sar-
coma as an attractive target for natural killer cell-based
immunotherapy.
Several phase I-III clinical trials now prove HDI-treat-
ment to be safe and effective in both hematological and
solid tumours (as reviewed by [56]) and recently, differ-
ent HDI were approved by the US Food and Drug
Administration for use in patients [57]. With regard to
Ewing sarcoma, a role for HDI in reversal of oncogenic
transcriptional repression has been proposed [58]. In
addition, HDI-mediated cytotoxicity has been demon-
strated both in vitro and in vivo and sensitization for
both conventional and more experimental treatment
modalities has been suggested [29,31,32]. Here, we
demonstrate the ability of three structurally different
HDI to, at doses 5-20 times lower than the established
IC50 values, improve potential immune recognition (by
natural killer cells and/or specific T-lymphocyte subsets)
of both chemotherapy-sensitive and -resistant Ewing
sarcoma. HDI-pretreatment resulted in ATM/ATR-
dependent induction of NKG2D ligands, in particular
MICA and MICB, in all cell lines. Moreover, dose-
dependent sensitization for natural killer cell cytotoxicity
was observed in 2/4 cell lines, including the chemother-
apy-resistant CADO-ES cell line. The doses used in
vitro were below or within the range of the maximum
tolerated dose as determined in recent clinical trials (in
children) [59,60]. Natural killer cell cytotoxicity
depended on NKG2D-NKG2D ligand interactions, since
blocking of NKG2D abrogated cytolysis. No sensitization
was observed for TC71 and STA-ET2.1 cells, despite
induction of NKG2D ligands. As yet, an adequate expla-
nation for this observation is lacking. Although HDI-
pretreatment induced HLA class I in these cell lines, a
contribution of dominant inhibitory signals provided by
this increased expression seems unlikely since HLA
class I blocking did not significantly affect natural killer
cell-mediated cytolysis.
Collectively, our data provide a rationale for combina-
tion immunotherapy involving immune effector cell (IL-
15-activated natural killer cells) and target cell (HDI)
manipulation in first- and/or second-line treatment regi-
mens for Ewing sarcoma.
Conclusions
Patients with Ewing sarcoma (EWS) have a poor prog-
nosis, despite current multimodal therapy. Integration of
immunotherapeutic strategies, including natural killer
(NK) cell-based therapies, into first-line treatment regi-
mens or introduction of these approaches as second-line
therapy may represent promising treatment options. Ex
vivo immune cell activation and/or (simultaneous)
sensitization of target cells for immune-mediated killing
by combination immunotherapy may overcome intrin-
sic/acquired resistance to conventional therapies and
improve (immuno)therapeutic efficacy. Here, we provide
the first evidence that combination immunotherapy
using histone deacetylase inhibitors and (interleukin-15-
activated) NK cells improves immune recognition of
both therapy-sensitive and -resistant EWS and sensitizes
for NK cell cytotoxicity. In vivo expression of activating
NK cell receptor ligands throughout all disease-stages,
regardless of chemotherapy-response, supports their
potential in vivo role in immune recognition of EWS.
Our data provide a rationale for combination immu-
notherapy involving simultaneous immune cell (interleu-
kin-15-activated NK cells) and target cell (histone
deacetylase inhibitors) manipulation in first-/second-line
treatment regimens for EWS.
Additional material
Additional file 1: Antibodies used for flow cytometry, NK cell
receptor (ligand) blocking, immunohistochemistry and ELISA.
Additional file 2: A. Constitutive surface expression of inhibitory
(HLA class I) or activating (MICA/B, ULBP1-3, CD112, CD155) natural
killer cell receptor ligands in chemotherapy-sensitive (grey) and
-resistant (black) Ewing sarcoma cell lines, as assessed by flow
cytometry. Results are expressed as the mean ± SD MFI-ratio, obtained
in at least two independent experiments. Statistical analysis (t-test) was
performed on mean MFI-ratio’s (for each ligand) of chemotherapy-
sensitive versus -resistant cell lines, revealing no significant differences in
expression levels of these ligands (p > 0.05). B. Cytotoxic activity of
resting natural killer cells was evaluated in 51Cr release assays using
chemotherapy-sensitive (TC71 (blue), SK-ES-1 (purple), SK-N-MC (pink))
and -resistant (STA-ET-2.1 (black), CADO-ES (dark grey), IOR/BER (light
grey)) Ewing sarcoma cell lines as target cells. Ewing sarcoma cells were
either left untreated (solid bars) or pre-incubated with HLA class I
blocking antibody DX17 (checked bars). Results are expressed as the
mean ± SD percentage of specific lysis obtained in at least two
independent experiments using different healthy donors.
Additional file 3: Cytotoxic activity of IL-15-activated natural killer
cells was evaluated in 51Cr release assays using chemotherapy-
sensitive (TC71 (blue), SK-ES-1 (purple)) and -resistant (STA-ET-2.1
(black), CADO-ES (grey) Ewing sarcoma cell lines as target cells.
Ewing sarcoma cells were either left untreated (solid bars) or pre-
incubated with NKG2D and DNAM-1 blocking antibodies (checked bars).
Results are expressed as the mean ± SD percentage of specific lysis
obtained in at least two independent experiments using different
healthy donors.
Additional file 4: A. Cytotoxicity of resting natural killer cells was
evaluated in 51Cr release assays using MS-275-pretreated TC71 and
STA-ET2.1 cells. Despite induction of activating NKG2D ligands, no
sensitization for natural killer cell cytotoxicity was detectable (at doses up
to 1/5 of IC50 value). Similar results were observed for both cell lines
upon pre-treatment with NaB and SAHA (not shown). Results are
expressed as the mean ± SEM percentages of specific lysis obtained in at
least two independent experiments using different healthy donors. B.
Upon HDI-pretreatment, persistent dependency of resting natural killer
cell-mediated cytotoxicity on signaling via activating receptor NKG2D
was demonstrated when 51Cr release assays were performed in the
presence of a blocking antibody against NKG2D. Blocking reduced
resting natural killer cell-mediated lysis of both untreated and HDI pre-
treated cells to similar levels, as demonstrated for CADO-ES upon pre-
treatment with NaB. Similar results were obtained for CADO-ES with MS-
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275 and SAHA, as well as for SK-ES-1 with SAHA (not shown). K562 and
EBV B-LCL cell line 107 were used as positive and negative control
respectively (not shown). Results are expressed as the mean ± SEM
percentages of specific lysis obtained in at least two independent
experiments using different healthy donors.
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